WALTER FRIED, M.D.; OLGA JONASSON, M.D.; GORDON LANG, M.D.; FRANKLIN SCHWARTZ, M.D., F.A.C.P.
Effects of testosterone propionate therapy (150 mg twice weekly) were observed in five anephric patients and in six patients with chronic renal failure who had not undergone nephrectomy. All of the patients were on the maintenance hemodialysis program for at least 6 months before the beginning of the study. The six patients with kidney remnants responded to therapy with a significant rise in both packed cell volume and plasma erythropoietin titer. None of the five anephric patients had an increase in either of these variables. Testosterone propionate causes a rise in the packed cell volume of patients with chronic renal failure, primarily by increasing erythropoietin production in the kidney remnants.
FRIED W, JONASSON O, LANG G, et al. The Hematologic Effect of Androgen in Uremic Patients: Study of Packed Cell Volume and Erythropoietin Responses. Ann Intern Med. 1973;79:823–827. doi: 10.7326/0003-4819-79-6-823
Download citation file:
© 2019
Published: Ann Intern Med. 1973;79(6):823-827.
DOI: 10.7326/0003-4819-79-6-823
Hematology/Oncology.
Results provided by: